Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05049057 · ClinicalTrials.gov registry record · Phase 2
Treatment of Acute PTH With a CGRP Receptor mAb in Military Service Members and Civilians With mTBI
A Phase 2 study of Mild Traumatic Brain Injury and Post-Traumatic Headache, sponsored by Henry M. Jackson Foundation for the Advancement of Military Medicine.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 404
- Enrollment target
- 4
- Study locations
NCT05049057: Recruiting Phase 2 study of Mild Traumatic Brain Injury and Post-Traumatic Headache, sponsored by Henry M. Jackson Foundation for the Advancement of Military Medicine.
NCT05049057 is a Phase 2 study of Mild Traumatic Brain Injury and Post-Traumatic Headache that is actively recruiting participants, run by Henry M. Jackson Foundation for the Advancement of Military Medicine. The registered enrollment target is 404 participants, above the 211-participant average among 43 other Mild Traumatic Brain Injury trials with a reported enrollment target (91% higher). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05049057, a Phase 2 study of Mild Traumatic Brain Injury and Post-Traumatic Headache, is actively recruiting participants, sponsored by Henry M. Jackson Foundation for the Advancement of Military Medicine.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 404 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study aims to assess the effect and safety of erenumab compared to placebo for the treatment of acute posttraumatic headache (PTH) in military service members and civilians with mild traumatic brain injury (mTBI).
Primary Outcome
Effect of erenumab versus placebo on monthly headache days as measured by the daily headache diary
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Erenumab 140 Mg/mL Subcutaneous Solution
Study Locations (4)
North Carolina
- Womack Army Medical Center - Fort Liberty - Fort Bragg
Pennsylvania
- University of Pittsburgh Concussion Research Laboratory - Pittsburgh
Texas
- William Beaumont Army Medical Center - El Paso
Washington
- Madigan Army Medical Center - Tacoma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 404 participants |
| Start Date | 2022-07-19 |
| Est. Completion | 2027-05-19 |
| Phase | Phase 2 |
What NCT05049057 shows while recruiting
NCT05049057 is an interventional study that assigns participants to a tested intervention. The registered 404 participants enrollment target is mid-sized for trials with a published cap, above the 211-participant average among 43 other Mild Traumatic Brain Injury trials with a reported enrollment target (91% higher).
The record links to 2 conditions, with Mild Traumatic Brain Injury appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05049057 reports a single indexed study location in North Carolina, Pennsylvania, Texas.
Frequently Asked Questions
What is clinical trial NCT05049057 about?
NCT05049057 is a clinical study titled "Treatment of Acute PTH With a CGRP Receptor mAb in Military Service Members and Civilians With mTBI". This study aims to assess the effect and safety of erenumab compared to placebo for the treatment of acute posttraumatic headache (PTH) in military service members and civilians with mild traumatic brain injury (mTBI).
What is the current status of trial NCT05049057?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 404 participants. The study started on 2022-07-19. Estimated completion is 2027-05-19.
What conditions does trial NCT05049057 study?
This clinical trial studies the following conditions: Mild Traumatic Brain Injury, Post-Traumatic Headache.
What interventions are being tested in trial NCT05049057?
The interventions under investigation include: Placebo (DRUG), Erenumab 140 Mg/mL Subcutaneous Solution (DRUG).
Who is sponsoring clinical trial NCT05049057?
This trial is sponsored by Henry M. Jackson Foundation for the Advancement of Military Medicine, which has 60 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05049057 being conducted?
This trial has 4 study locations across North Carolina, Pennsylvania, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mild Traumatic Brain Injury
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05049057's enrollment target sits among peer trials
404 7th of 43 higher than 37 of 43 other Mild Traumatic Brain Injury trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Mild Traumatic Brain Injury trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Personalized Brain Stimulation to Treat Chronic Concussive Symptoms
RECRUITING · Phase 2
-
Randomized Controlled Trial of Treatment to Optimize Heart Rate Variability for Persistent Post-Concussion Symptoms
RECRUITING · Phase 2
-
Pathways Relating Amnestic MCI to a Mild Traumatic Brain Injury History
RECRUITING · Phase 2
-
Pilot rTMS for AUD+mTBI
ACTIVE NOT RECRUITING · Phase 2
-
Hyperbaric Oxygen Therapy (HBO2T) for Post-Concussive Symptoms (PSC) After Mild Traumatic Brain Injury (mTBI)
COMPLETED · Phase 2
-
Concussion Recovery and Support Program
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05611242 · 404 participants · Phase 3
Proximal Internal Carotid Artery Acute Stroke Secondary to Tandem or Local Occlusion Thrombectomy Trial
- NCT06072612 · 404 participants · Phase 3
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
- NCT05576350 · 405 participants · NA
TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk
- NCT07066657 · 405 participants · Phase 1
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI